Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
Abstract Chimeric antigen receptors (CARs) are engineered to target T cells specifically to tumor cells, resulting in the engineered T cell killing the tumor cell. This technology has been developed to target a range of cancers, with the most notable successes in the treatment of B-cell malignancies...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2023-07-01
|
| Colección: | Journal of Translational Medicine |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s12967-023-04372-4 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|